Detection and characterization of circulating tumor cells in cancer patients
Completed
- Conditions
- Cancer spreadMetastasis10027656
- Registration Number
- NL-OMON34754
- Lead Sponsor
- niversiteit Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Minimal age 18 years
Diagnosis Stage IV solid carcinoma
Minimum of seven days since last therapie (exept daily administration therapies)
Signed informed consent form
Exclusion Criteria
Under the age of 18 years
Early stage disease
Patients unwilling/unable to give consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The blood specimens will be used to isolate, enumerate, and characterize the<br /><br>circulating cells. Fluorescently labeled antibodies for tumor specific and/or<br /><br>tissue specific markers among others will be used to identify, count and<br /><br>characterize the circulating cells. The blood samples and isolated cells may<br /><br>also be used for the detection of altered, over-, or under-produced<br /><br>cancer-related molecules, including gene expression studies of genes that may<br /><br>be related to the response of cancer cells to therapeutics. Genetic studies<br /><br>will be done to determine their importance in response to therapies, not to<br /><br>test for genetic sequences for the purpose of identifying inherited genetic<br /><br>disorders. Remaining blood samples and their components may be saved for<br /><br>possible use in future investigations related to cancer research, including<br /><br>detection of altered, over-, or under-produced cancer-related molecules.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>